BR112017009470A2 - síntese de copanlisib e seu sal de di-hidrocloreto. - Google Patents

síntese de copanlisib e seu sal de di-hidrocloreto.

Info

Publication number
BR112017009470A2
BR112017009470A2 BR112017009470A BR112017009470A BR112017009470A2 BR 112017009470 A2 BR112017009470 A2 BR 112017009470A2 BR 112017009470 A BR112017009470 A BR 112017009470A BR 112017009470 A BR112017009470 A BR 112017009470A BR 112017009470 A2 BR112017009470 A2 BR 112017009470A2
Authority
BR
Brazil
Prior art keywords
copanlisib
synthesis
dihydrochloride salt
dihydrochloride
hydrates
Prior art date
Application number
BR112017009470A
Other languages
English (en)
Other versions
BR112017009470B1 (pt
Inventor
Lender Andreas
Götz Daniel
Grossbach Danja
Mais Franz-Josef
Weingärtner Günter
Schirmer Heiko
Peters Jan-Georg
Stiehl Juergen
Lovis Kai
Seyfried Martin
Marty Maurus
Rubenbauer Philipp
Zweifel Theodor
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112017009470A2 publication Critical patent/BR112017009470A2/pt
Publication of BR112017009470B1 publication Critical patent/BR112017009470B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

a presente invenção está relacionada a um novo método de preparação de copanlisib, di-hidrocloreto de copanlisib ou hidratos de di-hidrocloreto de copanlisib, a novos compostos intermediários e ao uso dos novos compostos intermediários para a preparação do copanlisib, di-hidrocloreto de copanlisib ou hidratos de di-hidrocloreto de copanlisib. a presente invenção também está relacionada a hidratos de di-hidrocloreto de copanlisib como compostos.
BR112017009470-3A 2014-11-07 2015-11-05 Método para preparação de copanlisib, seu intermediário e seu uso BR112017009470B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14132203.9 2014-11-07
EP14192203.9A EP3018127A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075789 WO2016071435A2 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (2)

Publication Number Publication Date
BR112017009470A2 true BR112017009470A2 (pt) 2018-01-02
BR112017009470B1 BR112017009470B1 (pt) 2022-11-01

Family

ID=51866061

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009470-3A BR112017009470B1 (pt) 2014-11-07 2015-11-05 Método para preparação de copanlisib, seu intermediário e seu uso

Country Status (47)

Country Link
US (1) US10494372B2 (pt)
EP (2) EP3018127A1 (pt)
JP (1) JP6691115B2 (pt)
KR (1) KR102566834B1 (pt)
CN (1) CN107278204B (pt)
AR (1) AR102570A1 (pt)
AU (1) AU2015341788B2 (pt)
BR (1) BR112017009470B1 (pt)
CA (1) CA2966800C (pt)
CL (1) CL2017001131A1 (pt)
CO (1) CO2017004532A2 (pt)
CR (1) CR20170184A (pt)
CU (1) CU24489B1 (pt)
CY (1) CY1121602T1 (pt)
DK (1) DK3215493T3 (pt)
DO (1) DOP2017000112A (pt)
EA (1) EA035558B1 (pt)
EC (1) ECSP17027755A (pt)
ES (1) ES2721778T3 (pt)
HK (1) HK1245774A1 (pt)
HR (1) HRP20190720T1 (pt)
HU (1) HUE042866T2 (pt)
IL (1) IL251874A0 (pt)
JO (1) JO3644B1 (pt)
LT (1) LT3215493T (pt)
MA (1) MA40895B1 (pt)
ME (1) ME03358B (pt)
MX (1) MX366904B (pt)
MY (1) MY189852A (pt)
NI (1) NI201700054A (pt)
NZ (1) NZ731287A (pt)
PE (1) PE20170897A1 (pt)
PH (1) PH12017500833A1 (pt)
PL (1) PL3215493T3 (pt)
PT (1) PT3215493T (pt)
RS (1) RS58579B1 (pt)
SA (1) SA517381462B1 (pt)
SG (1) SG11201703702RA (pt)
SI (1) SI3215493T1 (pt)
SV (1) SV2017005433A (pt)
TN (1) TN2017000179A1 (pt)
TR (1) TR201905217T4 (pt)
TW (1) TWI697495B (pt)
UA (1) UA122398C2 (pt)
UY (1) UY36392A (pt)
WO (1) WO2016071435A2 (pt)
ZA (1) ZA201703867B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
CU24607B1 (es) 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas
WO2023139125A1 (en) 2022-01-18 2023-07-27 Synthon B.V. Improved process for preparation of copanlisib
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003580A (en) 1910-08-10 1911-09-19 Remington Typewriter Co Type-writing machine.
US6221877B1 (en) * 2000-04-12 2001-04-24 Regents Of The University Of California Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
EP1417204B1 (en) * 2001-08-15 2006-01-18 E. I. du Pont de Nemours and Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
ES2312843T3 (es) 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3077002B1 (en) 2013-12-03 2020-04-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
AU2016231260A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
AU2017214230A1 (en) 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
WO2017134030A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors

Also Published As

Publication number Publication date
HUE042866T2 (hu) 2019-07-29
SV2017005433A (es) 2018-04-30
JP2017534631A (ja) 2017-11-24
MX2017005893A (es) 2017-06-30
PL3215493T3 (pl) 2019-07-31
CR20170184A (es) 2017-06-20
ES2721778T3 (es) 2019-08-05
AR102570A1 (es) 2017-03-08
KR20170082563A (ko) 2017-07-14
EP3215493A2 (en) 2017-09-13
PH12017500833A1 (en) 2017-10-18
DK3215493T3 (da) 2019-05-06
LT3215493T (lt) 2019-04-25
DOP2017000112A (es) 2017-06-15
KR102566834B1 (ko) 2023-08-16
PE20170897A1 (es) 2017-07-12
AU2015341788B2 (en) 2020-01-16
MA40895A (fr) 2017-09-13
CY1121602T1 (el) 2020-05-29
SI3215493T1 (sl) 2019-05-31
CO2017004532A2 (es) 2017-07-19
NZ731287A (en) 2023-01-27
ECSP17027755A (es) 2017-06-30
SA517381462B1 (ar) 2021-01-25
CA2966800A1 (en) 2016-05-12
UA122398C2 (uk) 2020-11-10
IL251874A0 (en) 2017-06-29
BR112017009470B1 (pt) 2022-11-01
NI201700054A (es) 2017-07-17
WO2016071435A3 (en) 2016-06-30
ME03358B (me) 2019-10-20
EA035558B1 (ru) 2020-07-07
EA201790983A1 (ru) 2017-10-31
US20180282337A1 (en) 2018-10-04
MY189852A (en) 2022-03-14
CA2966800C (en) 2023-02-21
AU2015341788A1 (en) 2017-05-18
TN2017000179A1 (en) 2018-10-19
CU24489B1 (es) 2020-12-17
HK1245774A1 (zh) 2018-08-31
CL2017001131A1 (es) 2018-01-19
RS58579B1 (sr) 2019-05-31
SG11201703702RA (en) 2017-06-29
MA40895B1 (fr) 2019-07-31
US10494372B2 (en) 2019-12-03
JO3644B1 (ar) 2020-08-27
JP6691115B2 (ja) 2020-04-28
CN107278204B (zh) 2019-12-17
CU20170061A7 (es) 2017-10-05
TWI697495B (zh) 2020-07-01
HRP20190720T1 (hr) 2019-06-14
MX366904B (es) 2019-07-30
TR201905217T4 (tr) 2019-05-21
TW201625634A (zh) 2016-07-16
ZA201703867B (en) 2019-07-31
WO2016071435A2 (en) 2016-05-12
PT3215493T (pt) 2019-05-21
EP3018127A1 (en) 2016-05-11
EP3215493B1 (en) 2019-01-23
CN107278204A (zh) 2017-10-20
UY36392A (es) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112017009470A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
BR112017013767A2 (pt) uso de picolinamidas como fungicidas
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
EA201791645A1 (ru) Новые соли и полиморфы scy-078
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
BR112019000988A2 (pt) derivado de triazolopirazinona útil como inibidor de pde1 humana
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas
BR112017007011A2 (pt) compostos de metil-piperidina úteis para inibir a prostaglandina e2 sintase-1 microssômica
BR112016016361A2 (pt) Composto e método para preparação
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
IN2013MU02595A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 233/24 , C07D 487/04

Ipc: C07D 233/24 (2006.01), C07D 487/04 (2006.01), C07D

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2015, OBSERVADAS AS CONDICOES LEGAIS